All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1300+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Zeta Surgical lands expanded FDA clearance for “GPS-like” mixed-reality brain surgery navigation platform
Brain surgery, mixed reality, computer vision, AI - Read more

THE GOOD
Business Development

IDEAYA Biosciences exercises exclusive licensing option for Biocytogen’s ADC IDE034
Antibody-drug conjugate, solid tumor, cancer - Read more

THE GOOD
Clinical Trials

Relief Therapeutics positive final results for RLF-TD011 proof-of-concept trial in epidermolysis bullosa
Small mlecule, epidermolysis bullosa - Read more

Gan & Lee Pharmaceuticals GZR18 demonstrated “significant reduction in body weight” in Ph2 clinical trial of obese, overweight Chinese adults
GLP-1, obesity - Read more

Kanvas Bio posts promising clinical data in fecal microbiota transplantation effects on anti-PD-1 refractory cancers
Fecal microbiota transplantation, cancer, drug resistance - Read more

Novavax COVID-19, flu vaccines clinical holds lifted by the FDA
Vaccine, flu, COVID-19 - Read more

Boston Scientific resumes pulse-field ablation clinical trials in atrial fibrillation
Medical device, atrial fibrillation, pulsed field ablation - Read more

Pioneering medicine starts with investors like you.

Cizzle Biotech is transforming lung cancer detection with a patented, 95% accurate blood test. By joining our raise, you’ll gain ownership in a company backed by partnerships with Bio-Techne and Moffitt Cancer Center. You can build your portfolio with a stake in a medical breakthrough.

Join the Raise

^{Read the Offering information carefully before investing. It contains details of the issuer’s business, risks, charges, expenses, and other information, which should be considered before investing. Obtain a Form C and Offering Memorandum at invest.cizzlebio.com}

⬇️ More Good News ⬇️

THE GOOD
Fundraises

Novelty Nobility 23.3B KRW ($24.8M) Series C, initiating ADC NN3201 Ph1 trial next year
Antibody-drug conjugate, solid tumor, cancer - Read more [Press release in Korean]

EpiBone undisclosed equity raise, regenerative medicine focused on skeletal reconstruction
Stem cells, 3D bioprinting, bone and osteochondral reconstruction - Read more

THE GOOD
Investments

Genscript ProBio builds logistics hub in Australia amongst increasing US scrutiny to China ties
CDMO, manufacturing, reagents, logistics hub, Biosecure - Read more

THE GOOD
Mergers & Acquisitions

Evotec is an alleged acquisition target by private equity firm Triton Partners
CRO, CDMO, takeover rumors - Read more

General Catalyst to acquire Ohio-based hospital system Summa Health for $485M
Healthcare, hospital system - Read more

THE GOOD
Partnerships

ALK-Abelló purchases marketing right to ARS Pharmaceuticals’s EURneffy worldwide (except for US, Australia, New Zealand, Japan, China) for $145M upfront, $320M biobucks
Small molecule, anaphylaxis, nasal spray - Read more

THE GOOD
Patient Access

Doctors Without Borders (MSF) demands insulin pen makers Sanofi, Eli Lilly, Novo Nordisk reduce device costs to $1 in low- and middle-income countries
Insulin, diabetes, insulin pen - Read more

THE GOOD
Research

Lunit’s AI-based tumor biopsy analysis tool can help predict rare tumor responses to checkpoint inhibitors according to research from MD Anderson Cancer Center
Biopsy analysis, cancer, tumor microenvironment, AI - Read more

MD Anderson Cancer Center launches cell therapy discovery & clinical research institute with initial $80M, goal of $150M total funding (philanthropic and institutional funds)
Cell therapy, drug discovery, drug development, R&D - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

AbbVie’s $8.9B Cereval buy is looking like a complete dud after emraclidine flops in two key Ph2 trials
Small molecule, schizophrenia - Read more

THE BAD
Lawsuits

Aurion Biotech IPO plans go off-track as investor Alcon sues
Cell therapy, corneal endothelial dystrophies, eye disease - Read more [Paywall]

THE BAD
Layoffs

23andMe shutters therapeutic division with accompanying layoffs (40% of total staff)
Genetic testing, drug discovery - Read more

ThermoFisher telegraphs 160 layoffs across three viral vector facilities (with one of these facilities full shuttering)
Viral vectors, manufacturing - Read more

THE BAD
Mergers & Acquisitions

Cigna unequivocally confirms that it is not seeking an acquisition of Humana
Health insurance - Read more

THE BAD
Strategic Plans

Rapt Therapeutics throws in the towel on RPT193 development after negative FDA feedback, stock nearly halves
Small molecule, atopic dermatitis, asthma - Read more

THE UGLY
Earnings & Finances

Assertio and activist investor The Buxton Helmsley Group trade blows over fraud allegations
Small molecule, short position, activist investor - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here